Journal of the National Comprehensive Cancer Network

Papers
(The H4-Index of Journal of the National Comprehensive Cancer Network is 53. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
CLO23-035: Expression of PD-L1 Through Evolution Phase From Pre-Invasive to Invasive Lung Adenocarcinoma742
HSR23-103: Pancreatic Cancer: The Impact of Early Connectivity and Coordination of Care on Retention and Time to Treat726
CLO23-045: A Prospective Interventional Study to Assess the Response of Systemic Chemotherapy in Aggressive, Recurrent Giant Cell Tumor599
CLO23-043: Optimal Interval Between Immune Therapy and Targeted Therapy With Sotorasib in Patients With KRAS G12C Mutant Non–Small Cell Lung Cancer556
My Report Card503
Highlights of the NCCN Oncology Research Program481
EHR-Integrated Patient-Reported Outcomes in Ambulatory Oncology: A Critical Opportunity for Timely and Targeted Palliative Care457
HSR24-169: Autonomic Symptoms May Suggest Paraneoplastic Neurological Syndromes in Small Cell Lung Cancer438
HSR24-153: Real-World Clinical Outcomes of First-Line Therapies and Treatment Regimens for BRAF-Mutant Advanced/Metastatic Melanoma: Retrospective Observational Study426
CRE24-049: Extrapulmonary Small Cell Carcinoma of Gallbladder Presenting as Acute Cholecystitis377
HSR24-127: Rectal Cancer Disparities in Age and Overall Survival Among American Indian and Alaska Native Vs Non-Hispanic White Populations375
CLO24-055: Outcomes With Sacituzumab Govitecan in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis278
EPR24-113: The Role of Social Determinants of Health in Gastrointestinal Cancer Outcomes in the United States Context: A Systematic Review273
HSR24-163: Comparative Assessment of Social Determinants of Health in Community and Academic Hospitals for Patients Diagnosed With Hepatocellular Carcinoma272
Relapsed/Refractory CLL/SLL: Overcoming Resistance to Covalent BTKi and/or BCL2 Inhibitors266
Highlights of the NCCN Oncology Research Program242
NCCN News232
Highlights of the NCCN Oncology Research Program201
A New Administration and JNCCN195
BPI25-005: Molecular Biomarker Testing Patterns and Turn-Around Time in US Patients With Advanced Non-Small Cell Lung Cancer179
BPI25-019: Empirical Study to Estimate Real World Impact of Delay in EGFR Testing on Healthcare Resource Utilization and Cost Burden Among Early-Stage NSCLC Patients173
BIO25-027: Addressing Early Diagnosis Challenges: Utilizing C the Signs Clinical Decision Support Platform for Pancreatic Cancer Risk Assessment172
Advances in the Treatment of Recurrent Ovarian Cancer and Rare Malignant Ovarian Germ Cell Tumors162
HSR24-152: Patient-Reported Outcome (PRO) Data in Oncology NDAs Approved by the FDA (2018–2021): A Review of Criticism and Concerns in Comments From Regulators147
EPR24-099: Clinical and Epidemiological Characterization of the Oncologic Population in a Third Level Hospital in Northeastern Mexico145
YIA24-005: MAIT Cells are Reduced in Anorectal Mucosal Melanomas Compared to Cutaneous Melanoma GI Metastases139
CLO24-060: Organomegalies as a Predictive Indicator of Leukemia Cutis in the Patients With Acute Myeloid Leukemia133
EPR25-138: Glioblastoma Multiforme: A SEER STAT Analysis of Epidemiological, Laterality, and Anatomical Prognostic Indicators132
HSR25-181: Assessment of Content Validity of the Functional Assessment of Cancer Therapy – Cutaneous T-Cell Lymphoma (FACT-CTCL)127
HSR25-141: Adolescent and Young Adult Cancer Patients: Our Most Financially Vulnerable Demographic123
CLO25-078: Deciphering Risk of Early Biochemical Recurrence in Prostate Cancer Prior to Definitive Therapy122
EPR25-128: Epidemiology of Olfactory Neuroblastoma: A SEER Stat Review118
Highlights of the NCCN Oncology Research Program116
HSR26-266: Navigating the Burden of Cure: Defining Survivorship Pathways in Head and Neck Cancer116
EPR26-166: Food Insecurity and Healthcare Utilization Among Cancer Survivors - Pre and Post COVID-19116
CLO26-089: Open Radical Cystectomy in the Current Era: Perioperative Outcomes From a Single Institutional Experience113
QIM26-305: Central Fill Optimization to Reduce Drug Waste and Enhance Multidisciplinary Workflow Within an Ambulatory Infusion Suite99
CGE26-135: Differential Germline Mutation Spectrum Analysis in Familial and Inherited Breast Cancer Patients in Pakistan96
CLO26-115: Association Between Geriatric Assessment Variables and Treatment Completion in Older Adults With Triple-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy and Immunotherapy: The MSKC93
BPI26-019: Comparison of Dosimetric Parameters of Organs at Risk Using Two Different Methods of Contouring in Head Neck Cancer Volumetric Arc Radiotherapy92
EPR26-152: GLP-1 and Dual Agonists and the Incidence of Skin Cancer: Evidence from Randomized Controlled Trials88
CLO26-131: Hematologic–IHC Prognostic Score for Therapeutic Prioritization in Breast Cancer: Multicenter Validation in Peru (2010–2020)87
HSR26-231: Diagnostic Performance of the Bexa™ Breast Exam for Detection of Breast Masses: A Prospective Single-Center Study83
Academic Oncology at a Crossroads: Rebuilding a Sustainable Career Path72
Proportion of Gleason Score ≥8 Prostate Cancer on Biopsy and Tumor Aggressiveness in Matched Cohorts of East Asian and Non-East Asian Men70
NCCN News70
Statin Use During Concurrent Chemoradiotherapy for Advanced Nasopharyngeal Cancer67
Evaluation of NCI-Designated Cancer Center and Comprehensive Cancer Center Survivorship-Focused Websites: Information Provided and Accessibility62
The Association of Extended Venous Thromboembolism Prophylaxis and Venous Thromboembolism After Cancer Surgery62
Intravenous Patient-Controlled Analgesia Versus Oral Opioid to Maintain Analgesia for Severe Cancer Pain: A Randomized Phase II Trial60
Impact of the French ENDOCAN–COMETE Network on Overall Survival in Rare Adrenocortical Carcinomas57
Advances in Early-Stage Colorectal Cancer Care: Integrating Emerging Evidence Into Practice55
Selecting the Optimal Treatment Approach for Patients With Metastatic Prostate Cancer54
Empowering Care Teams: Redefining Message Management to Enhance Care Delivery and Alleviate Oncologist Burnout53
0.53758311271667